Pathogenesis, prevention, and management of bleeding and thrombosis in patients with liver diseases

Research output: Contribution to journalReview articlepeer-review

95 Citations (Scopus)
251 Downloads (Pure)


Patients with liver diseases may develop alterations in all components of the hemostatic system. Thrombocytopenia, low levels of coagulation factors and inhibitors, low levels of fibrinolytic proteins, and increased levels of endothelial-derived proteins such as von Willebrand factor are all part of the coagulopathy of liver disease. Due to concomitant changes in pro- and antihemostatic drivers, the net effects of these complex hemostatic changes have long been unclear. According to current concepts, the hemostatic system of patients with liver disease is in an unstable balance, which explains the occurrence of both bleeding and thrombotic complications. This review will discuss etiology and management of bleeding and thrombosis in liver disease and will outline unsolved clinical questions. In addition, we will discuss the role of intrahepatic activation of coagulation for progression of liver disease, a novel paradigm with potential consequences for the general management of patients with liver disease.

Original languageEnglish
Pages (from-to)150-161
Number of pages12
JournalResearch and practice in thrombosis and haemostasis
Issue number2
Publication statusPublished - Oct-2017

Cite this